Scailyte, a BioTech firm based in Sursee in the canton of Lucerne, has agreed a strategic partnership with Geninus, a spin-off from the South Korean Samsung Genome Institute. Both companies believe that together they can make huge progress in the treatment of non small-cell lung carcinoma (NSCLC). At 25 percent, this is the cancer indication with the highest mortality rate around the world.
According to a press release issued by Scailyte, the two companies will now combine “their unique expertise in data generation and analysis”. Geninus will bring a variety of cutting-edge genomic analysis technologies in addition to experienced global research and development specialists to the table, while Scailyte, which is a spin-off from the Swiss Federal Institute of Technology in Zurich (ETH), has developed a software solution on the basis of Artificial Intelligence (AI) that can significantly speed up the analysis of millions of individual cells. In this process, algorithms are used to connect the dots between a disease and certain conspicuous cell types and patterns. The platform therefore helps to uncover biomarker profiles that indicate the likelihood of the onset of complex diseases, which allows targeted therapies to be organized at an early stage.
Ultimately, these joint efforts should result in patients suffering from NSCLC being tested for their responsiveness to immune checkpoint inhibitor (ICI) therapy. This means that clinicians would have the tools required to make an informed therapeutic decision. In addition, Scailyte intends to investigate new biological and therapeutic approaches on the basis of molecular markers that define response to ICI.
Prof. Dr. Woong-Yang Park, founder and CEO of Geninus, summarizes the joint efforts being made by the two companies in the press release: “We hope to provide prognostic methods for immunotherapy response in precision medicine clinics through collaboration with Scailyte”.